Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Hogarty

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Blood Advances|May 13, 2026
Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosisBarbara A Degar, Oussama Abla, Patrick K Campbell, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2022
Epigenetic state determines inflammatory sensing in neuroblastomaAdam J Wolpaw, Liron D Grossmann, Jessica L Dessau, et al.
Frontiers in Immunology|June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyAmy K Erbe, Wei Wang, Patrick K Reville, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Journal of Pediatric Surgery|September 24, 2024
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Erin G Brown, E Stanton Adkins, Peter Mattei, et al.
Oncotarget|February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology groupRisa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.
Nature|September 24, 2025
Reprogramming neuroblastoma by diet-enhanced polyamine depletionSarah Cherkaoui, Christina S Turn, Yuan Yuan, et al.
Nature Communications|October 15, 2020
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterationsSamuel W Brady, Yanling Liu, Xiaotu Ma, et al.
Pediatric Blood & Cancer|June 30, 2012
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology CommitteeRie Suganuma, Larry L Wang, Hideki Sano, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Blood Advances|May 13, 2026
Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosisBarbara A Degar, Oussama Abla, Patrick K Campbell, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2022
Epigenetic state determines inflammatory sensing in neuroblastomaAdam J Wolpaw, Liron D Grossmann, Jessica L Dessau, et al.
Frontiers in Immunology|June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyAmy K Erbe, Wei Wang, Patrick K Reville, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Journal of Pediatric Surgery|September 24, 2024
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Erin G Brown, E Stanton Adkins, Peter Mattei, et al.
Oncotarget|February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology groupRisa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.
Nature|September 24, 2025
Reprogramming neuroblastoma by diet-enhanced polyamine depletionSarah Cherkaoui, Christina S Turn, Yuan Yuan, et al.
Nature Communications|October 15, 2020
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterationsSamuel W Brady, Yanling Liu, Xiaotu Ma, et al.
Pediatric Blood & Cancer|June 30, 2012
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology CommitteeRie Suganuma, Larry L Wang, Hideki Sano, et al.
Pageof 11